NCT06594965View on ClinicalTrials.gov

A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

176

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2026

Conditions

Myelodysplastic SyndromesAnemiaMDSBone Marrow Disease

Interventions

DRUG

HS-20106

HS-20106 administered subcutaneously every 4 weeks for up to 6 cycles. Eligible participants may be able to continue to receive subcutaneously administered HS-20106 after completing 6 cycles in the extended treatment period.

Trial Locations (1)

Unknown

Institute of Hematology and Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY

NCT06594965 - A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter